Is Transcode Therapeutics, Inc. (RNAZ) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 66.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 66.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.5% / 33% | 79.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 66.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.5% / 33% | 79.7% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -1763.0% | |
| Return on Assets (ROA) | -232.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$13M |
| Free Cash Flow | -$13M |
| Total Debt | $38,291 |
| Current Ratio | 1.6 |
| Total Assets | $7M |
Price & Trading
| Last Close | $8.54 |
| 50-Day MA | $9.62 |
| 200-Day MA | $9.85 |
| Avg Volume | 264K |
| Beta | 1.5 |
|
52-Week Range
$6.08
| |
About Transcode Therapeutics, Inc. (RNAZ)
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Transcode Therapeutics, Inc. (RNAZ) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Transcode Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Transcode Therapeutics, Inc.'s debt ratio?
Transcode Therapeutics, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.5%.
What are Transcode Therapeutics, Inc.'s key financial metrics?
Transcode Therapeutics, Inc. has a market capitalization of $8M. Return on equity stands at -1763.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.